Guangdong Traditional Chinese Medicine Health Fund

Guangdong Traditional Chinese Medicine Health Fund is an investment firm.

Active

Updated: Feb 15, 2026 ·

About

Guangdong Traditional Chinese Medicine Health Fund operates as an investment fund, managed by a collaboration between China Development Bank Financial and Guangdong Hengjian Holdings. The fund focuses its investment activities within the healthcare sector, particularly in areas related to traditional Chinese medicine and advanced medical technologies. It participates in funding rounds for companies developing innovative solutions in these fields.

The fund has been noted for its investments in biotechnology and pharmaceutical companies. For instance, it participated in the Series B2 financing round for Lion TCR, a company focused on mRNA-encoding TCR T-cell therapy for solid tumor treatment. Additionally, the fund has invested in Jun Shengtai, contributing to its Series C funding round.

Financial History

Total Raised

N/A

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Feb 10, 2026	Transcend Vivoscope	$14.5M Series B	—	Beijing Medical and Health Industry Investment Fund, Haikai Holdings Group, Tianjin Heying Haihe Brain-Machine Fund, Zhongguancun Science City Science

Financial History

Total Raised

N/A

Valuation

N/A

Deep Dive

The Guangdong Traditional Chinese Medicine Health Fund is an investment vehicle structured to channel capital into the healthcare industry, with a specific emphasis on traditional Chinese medicine and related health technologies. Its operational management is a joint effort between China Development Bank Financial and Guangdong Hengjian Holdings, leveraging the expertise and resources of both entities in the financial and investment sectors.

The fund's investment strategy targets companies that are developing and commercializing advancements in healthcare. This includes enterprises engaged in biotechnology, pharmaceuticals, and other medical innovations. Its portfolio reflects an interest in emerging therapies and healthcare solutions that align with its core focus areas.

Notable investments by the Guangdong Traditional Chinese Medicine Health Fund include its participation in the Series B2 financing round for Lion TCR. This investment supported Lion TCR's work in developing mRNA-encoding TCR T-cell therapy, a cutting-edge approach to treating solid tumors. Such engagements highlight the fund's commitment to supporting innovative medical research and development.

Another key investment is in Jun Shengtai, where the fund contributed to the company's Series C funding round. These investments demonstrate the fund's active role in providing growth capital to companies at various stages of development within the healthcare and life sciences sectors.

The fund frequently collaborates with other investment institutions in its financing activities. It has forged partnerships with various esteemed investment institutions, including Jingwei, Nuclear Power High-Tech, PICC Capital Equity Investment, and Shenzhen Capital Group. These collaborations enable the fund to participate in larger and more complex investment rounds, broadening its impact within the venture ecosystem.

Through its strategic investments and partnerships, the Guangdong Traditional Chinese Medicine Health Fund aims to foster the growth of companies that contribute to the evolution of healthcare, particularly within the context of traditional Chinese medicine and modern medical science. Its involvement helps drive innovation and expand access to advanced healthcare solutions.

Sources

Frequently Asked Questions

Who manages the Guangdong Traditional Chinese Medicine Health Fund?

The fund is managed by a collaborative effort between China Development Bank Financial and Guangdong Hengjian Holdings, combining their financial and investment expertise.

Can you name some companies the Guangdong Traditional Chinese Medicine Health Fund has invested in?

The fund has invested in companies such as Lion TCR, which is developing mRNA-encoding TCR T-cell therapy, and Jun Shengtai, contributing to its Series C funding round.